Fidia harnesses the regenerative power of Hyaluronic Acid with its innovative portfolio launched in Spain
• Hyaluronic acid is well-known for its hydrophilic property, providing excellent skin hydration and structure, therefore, used widely in aesthetic industry. What is less known is the biological actions this endogenous molecule performs at particular low molecular weights.
• Recently the Italian multinational Fidia Farmaceutici, world leader in the manufacture of Hyaluronic Acid-based products, presented its Aesthetic Care portfolio in Monaco during the Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC)
• The company is now launching its complete Hyal System and Hy-Tissue portfolio in Spain. Available from the month of April, aesthetic doctors can tap into a new era of biostimulation with the innovative Hyal System line and offer their patients a new approach in aesthetic treatments.
Fidia Farmaceutici – the world’s leading Italian multinational manufacturer of Hyaluronic Acid-based products available in more than 100 countries – presented its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo.
True to its vocation to create solutions aimed at improving people’s quality of life, Fidia is today one of the world’s leading pharmaceutical players in the manufacture of Hyaluronic Acid-based products, utilizing the regenerative potential of the endogenous molecule in a number of therapeutic areas. With more than 1,300 patents and over 55 years of research and sales on the Hyaluronic Acid molecule, the company now enters into Spanish aesthetics market with its innovative Hyal System and Hy-Tissue portfolios, available from April, offering aesthetic care solutions that preserve the person’s natural beauty and unique identity.
An innovative range harnessing the regenerative potential of Hyaluronic Acid
Hyaluronic acid is a natural component of the ECM (Extra Cellular Matrix) in our body and is particularly hydrophilic when it has a high molecular weight, which contributes to its skin hydrating capabilities, while at a low molecular weight, Hyaluronic Acid performs several biological actions.
Fidia’s innovative Hyal System Line, which has its origin in the Weight – Concentration – Technology (WCT) concept, is combining these three variables to exploit different properties of Hyaluronic Acid so that each product brings out different targeted benefits. The patented ACP technology emerging from this line is globally unique and enables a gradual release of highly pure LMW-HA. With this unique technology, the company is offering aesthetic doctors to tap into a new era of biostimulation, helping them to achieve more natural and durable rejuvenation effect with their patients.
To tackle the challenges in the field of regenerative medicine, Fidia offers the Hy-Tissue products, adding a diverse portfolio of products that allow to obtain to obtain high quality, safe and effective autologous PRP and nanofat at the point of care, allowing physicians to tailor the best science-based regenerative treatments for each patient.
To Carlo Pizzocaro, President and CEO of Fidia, entering into global aesthetics market means widening Fidia’s scope of physicians, helping them provide unique, safe, science based aesthetic treatment options for their patients. ‘’We pride ourselves with our dedication to science and research for the past 60 years, and today we are excited to bring our expertise and unique technologies to the medical aesthetics field in Spain, after our successful launch in Italy. With ‘care for the patient’ at our core, we aim to help physicians advance their aesthetic treatments, enabling them achieve more natural and durable results for their patients.’’ stated Mr. Pizzocaro, noting the regional expansion will continue throughout the year.